256. 筋型糖原病 Muscle glycogenosis Clinical trials / Disease details
臨床試験数 : 180 / 薬物数 : 133 - (DrugBank : 29) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05734521 (ClinicalTrials.gov) | October 26, 2022 | 3/2/2023 | Avalglucosidase Alfa Pregnancy Study | A Descriptive Safety Study Based on Data Collected From Women and Their Offspring Exposed to Nexviazyme/Nexviadyme (Avalglucosidase Alfa-ngpt/Avalglucosidase Alfa) During Pregnancy and/or Lactation in the Postmarketing Setting | Pompe Disease;Pregnancy | Biological: avalglucosidase alfa-NGPT (GZ402666) IV;Biological: avalglucosidase alfa-NGPT (GZ402666) | Sanofi | NULL | Recruiting | N/A | N/A | Female | 100 | United States |